Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension
Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension
This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo
 in patients with hypercholesterolemia and hypertension.
Inclusion Criteria:

 -  Mean 24-hour ambulatory SBP greater than or equal to 130 mmHg

 -  or- Mean 24-hour ambulatory DBP greater than or equal to 80 mmHg

 -  Fasting LDL-C between 100 and 220 mg/dL

 -  Fasting triglycerides less than 400 mg/dL

 -  Body mass index (BMI) between 18 and 45 kg/m2

 Exclusion Criteria:

 -  Known or suspected secondary hypertension or history of malignant hypertension

 -  Taking more than two anti-hypertension medications at the first visit

 -  History or current clinically significant cardiovascular disease

 -  History or current type 1 diabetes or type 2 diabetes